CPT1C

Across TCGA pan-cancer cohorts, CPT1C RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CPT1C’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CPT1C RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CPT1C is over-expressed in tumor, although a few such as KICH and KIRP show the opposite, repressed pattern.

LIHC, KICH, and KIRC are the cancer types where CPT1C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CPT1C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.653	<.001	8	view →
KICH	Male	All	−0.910	<.001	7	view →
KIRC	Male	All	+0.397	<.001	5	view →
LUAD	All	All	+0.361	.004	4	view →
CHOL	All	All	+0.763	.002	3	view →
LUSC	All	All	+0.602	.003	3	view →
HNSC	All	All	+0.381	.007	3	view →
READ	Male	All	+1.080	.037	2	view →
THCA	Female	All	+0.661	<.001	2	view →
KIRP	Male	All	−0.479	<.001	2	view →
PRAD	All	All	−0.373	<.001	2	view →
READ	Female	All	−0.580	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 11 lineages.

CPT1C–LIHC

Open the LIHC breakdown →